The possibility of phosphodiesterase 4 inhibitors as drug therapy for idiopathic pulmonary fibrosis

Yating LI; Miaomiao LIU; Jinhui XU; Xingdong WU; Haobin ZHU; Hongmei YUE.
Chinese Journal of Clinical Pharmacology and Therapeutics ; (12): 818-823, 2023.
Artículo en Zh | WPRIM | ID: wpr-1014623

Documentos relacionados

  1. Fenbendazole Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice via Suppression of Fibroblast-to-Myofibroblast Differentiation.
  2. Fibroblast Diversity and Epigenetic Regulation in Cardiac Fibrosis.
  3. Dissecting Fibroblast Heterogeneity in Health and Fibrotic Disease.
  4. Investigating the Effect of Substrate Stiffness on the Redox State of Cardiac Fibroblasts Using Scanning Electrochemical Microscopy.
  5. Machine Learning and Single-Cell Analysis Identify Molecular Features of IPF-Associated Fibroblast Subtypes and Their Implications on IPF Prognosis.
  6. Role of Immune Cells in the Initiation and Progression of Pulmonary Fibrosis.
  7. The inhibition of human lung fibroblast proliferation and differentiation by Gs-coupled receptors is not predicted by the magnitude of cAMP response.
  8. Heterotypic tumor spheroids: a platform for nanomedicine evaluation.
  9. Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis.
  10. A Novel Role of Cyclic Nucleotide Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction.